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Abstract: Biallelic mutations in RECQL4 gene, a caretaker of the genome, cause Rothmund-Thomson
type-II syndrome (RTS-II) and confer increased cancer risk if they damage the helicase domain.
We describe five families exemplifying clinical and allelic heterogeneity of RTS-II, and report the
effect of pathogenic RECQL4 variants by in silico predictions and transcripts analyses. Complete
phenotype of patients #39 and #42 whose affected siblings developed osteosarcoma correlates with
their c.[1048_1049del], c.[1878+32_1878+55del] and c.[1568G>C;1573delT], c.[3021_3022del] variants
which damage the helicase domain. Literature survey highlights enrichment of these variants
affecting the helicase domain in patients with cancer outcome raising the issue of strict oncological
surveillance. Conversely, patients #29 and #19 have a mild phenotype and carry, respectively, the
unreported homozygous c.3265G>T and c.3054A>G variants, both sparing the helicase domain.
Finally, despite matching several criteria for RTS clinical diagnosis, patient #38 is heterozygous for
c.2412_2414del; no pathogenic CNVs out of those evidenced by high-resolution CGH-array, emerged
as contributors to her phenotype.
Keywords: Rothmund-Thomson syndrome; RECQL4; clinical expressivity; transcript analysis;
osteosarcoma outcome
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1. Introduction
Rothmund-Thomson syndrome (RTS, MIM#268400) is a rare autosomal recessive genodermatosis,
characterized by wide clinical expressivity, primarily accounted by locus heterogeneity, but to be
further deepened considering allele heterogeneity and genetic modifiers [1]. Approximately 400 RTS
patients are reported in the literature and generally all present as a hallmark sign the cutaneous
erythematosus rash appearing within the first two years of life at sun-exposed areas, mainly on the
face, then evolving into post-inflammatory chronic poikiloderma, a permanent lesion characterized by
skin atrophy with hypo- and hyper-pigmented areas and telangiectasia [2]. Other common features
manifested in early childhood are growth delay, hyperkeratosis and sparse and thin hair, eyelashes
and eyebrows, while premature aging is observed in adult age [2]. However, only two-thirds of
clinically diagnosed patients have biallelic alterations in RECQL4 gene (MIM#603780) which encodes a
protein belonging to RecQ helicase family, represented in human by five members (RECQL1, BLM,
WRN, RECQL4 and RECQL5) all with a fundamental role in safeguarding genome stability [3].
The predominant subset of RECQL4-mutated patients represents RTS type-II or Thomson-like entity,
characterized by poikiloderma, skeletal defects and cancer predisposition (osteosarcoma (OS) and less
frequently squamous cell carcinoma of the skin, hematological tumors and other malignancies) [4,5].
The RTS type-I or Rothmund-type includes by definition patients negative to RECQL4 mutations
who present like the RTS-II ones poikiloderma, ectodermal dysplasia and growth retardation but
differ in displaying the hallmark sign of bilateral juvenile cataracts: the RTS-I genetic defect is so far
unknown [1].
Intriguingly, the most fearful sign of cancer predisposition, together with genome instability and
premature aging, is shared by RTS-II, Bloom (MIM#210900) and Werner (MIM#277700) syndromes,
all caused by defective functioning of RecQ helicases [6]. In addition to RTS, RECQL4 biallelic
alterations are also responsible for Baller-Gerold (BGS, MIM#218600) and RAPADILINO (MIM#266280)
syndromes. All three RECQL4-associated diseases are clinically characterized by growth delay, bone
alterations and cancer predisposition, and the underlying biallelic pathogenic variants exert their effect
by a loss-of-function mechanism [7]. RTS is the most prevalent and hence best characterized entity,
while RAPADILINO is a Finnish inheritance disorder so far reported in about 20 cases [8] and BGS is
even rarer with less than a dozen of cases confirmed by molecular diagnosis [9].
TheRECQL4 gene, mapping to 8q24, encodes for a 1208 amino acids DNA helicase, a multi-domain
protein with a multi-functional role in essential processes of DNA metabolism, including DNA
replication [10], DNA repair of double-strand breaks [11], nucleotide excision repair [12] and base
excision repair [13], telomere maintenance [14], p53 transport to mitochondrion [15] and mitochondrial
DNA biogenesis [16].
Like the other members of RecQ family, RECQL4 protein is characterized by the central highly
conserved RecQ helicase domain (spanning amino acid residues 489–850 and encoded by exons 8–15),
while the N- and the C-terminal are unique among the family members. The RECQL4 N-terminus,
a Sld2-like domain (1–388 aa residues), essential for the initiation of DNA replication shows at least
two nuclear targeting signals (encompassing amino acids 37–66 and 363–492) [3,17]; a stretch of lysine
residues (aa 376–386) subject to p300 acetylation [18] and a mitochondrial localization sequence (first
84 amino acids) [15]. At the C-terminal a R4ZBD domain (aa 836–1045) [19], structurally different but
functionally comparable to RQC domain [20], and potential nuclear export signals are found [21].
The involvement of different RECQL4 domains in carrying on the multiple functions needed
for the safeguard of genome stability predicts a notable heterogeneity of mutant alleles depending
on their intragenic location and their combination, considering the known prevalence of compound
heterozygous versus homozygous genotypes reported for RTS patients [1]. While pathogenic variants
disrupting the helicase domain are classified as deleterious for RECQL4 as well as for WRN and
BLM, variants in the N-terminus region of RECQL4, which for its role in DNA replication initiation
and replication fork progression is indispensable for cell viability [22], have likely a sub-lethal effect,
consistent with the few mutations, never in the homozygous condition, identified in this region [7].
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Current poor knowledge of the specific roles of RECQL4 domains and subdomains precludes to rank
different mutations according to the compromised domains and functions, but the increasing number
of novel characterized pathogenic variants makes it worthwhile to detail the spectrum of the observed
RTS phenotypes, especially as regards cancer outcome.
We herein report on five unrelated families with RTS-II affected members who highlight the huge
variability of the clinical presentation depending on the strength of the underlying pathogenic variants
and their homozygous or heterozygous combination. We have characterized the causative RECQL4
genetic lesions and have explored their pathogenic effect by in silico predictions and transcripts
analyses to address mutation-phenotype correlation, especially in relation to cancer development.
2. Results
Five families (A, B, C, D, E) with one or more siblings clinically diagnosed with RTS were referred
to our laboratory for RECQL4 molecular analysis. Genealogic, clinical and molecular data are provided
in Figure 1, panels a, b, c, d and e, respectively.
Details on the cutaneous, skeletal, gastrointestinal findings, cancer development and RECQL4
genotypes, either assessed or inferred, are provided for all patients in Table 1.
2.1. Clinical Report of RTS Patients
2.1.1. Family A
Patient #29 (II-1) is a boy of Ecuadorian origin, who was adopted by an Italian couple.
The adoptive parents referred to poikiloderma onset at 6–7 months, first on cheeks, then spreading
to arms and forearms. They also noted photosensitivity and growth delay starting at pediatric age.
At the first dermatologic evaluation at age 14 years (y), the boy showed poikiloderma on sun-exposed
body sites (face, limbs and buttocks) and slight hypotrichosis of lateral third of eyebrows (Figure 1a).
He presented linear hyperkeratotic papule on the ventro-dorsal junction of both hands and feet,
some hyperkeratotic areas on the palms, soles and on the knuckles and onychodystrophy (Figure 1a).
He did not show radial ray defects, but osteosonography evidenced phalangeal hypodensity. At eye
examination, keratoconus was observed (Table 1).
Stature at age of 16 years was 157 cm (<3rd percentile) and weight 60.6 kg (25th–50th percentile).
Check-up for skin and bone cancer as well as hematological cancer is negative at the current age of
19 years.
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Figure 1. Clinical and molecular characterization of the five (A, B, C, D, E) RTS families. For each family, pedigree is furnished at the top, pictures of the major features
in the middle and electropherograms of RECQL4 pathogenic variants in the bottom panels. (a) Patient #29 (family A) at age 16y: poikiloderma on face and hand,
sparse eyebrows, hyperkeratotic areas on the knuckles and onychodystrophy can be observed. The homozygous c.3236G>T transversion in exon 18 is squared in
blue. (b) Facial poikiloderma of the living siblings of family B, III-3 (#39) and III-2 at 5 and 19 years, respectively; right ankle radiography of III-2 showing a lytic
focal eccentric lesion (21 × 20 × 40 mm) with “bubble” pattern and geographical margins on the side of the distal epiphyseal-metaphyseal region of the tibia. Facial
poikiloderma and severe plantar hyperkeratosis of the deceased elder sister III-1 at 23y and left elbow radiography of III-1 showing a lytic lesion in the olecranon with
permeative appearance and ill-defined contours with neoplastic appearance of bone matrix. The sibship c.1048_1049del in exon 5 and c.1878+32_1878+55del in intron
11 variants are squared in orange. (c) Patient #42 (family C): poikiloderma, sparse eyebrows and absent eyelashes can be appreciated on the face; notable plantar
hyperkeratosis, in particular on the heel, is observed. Exon 9 c.[1568G>C;1573delT] and exon 17 c.3021_3022del alterations are squared in green. (d) Patient #19
(family D): poikiloderma on cheeks and ear (age 5y); poikiloderma on forearm and keratoderma over the phalangeal joints can be seen (age 16y). The c.3054A>G
pathogenic variant affecting the penultimate nucleotide of exon 17 is squared in purple. (e) Patient #38 (family E): face image showing fine and sparse hair, eyelashes
and eyebrows. Plantar hyperkeratosis and cutaneous small white papule (arrowed) on the forearm can be observed. The c.2412_2420del alteration in exon 14 is
evidenced by a grey square. (f) RECQL4 intragenic location of the pathogenic variants is arrowed. A color-code is used to match mutations to index cases of the
different families. RECQL4 helicase domain is shaded in blue.
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Table 1. Clinical characteristics of affected individuals from RTS families.
Family A B C D E
Pedigree position II-1 III-1 III-2 III-3 II-2 II-6 IV-2 II-1
Index case code #29 - - #39 #42 - #19 #38
Birth/death 1995 1989-2013 1993 2008 1986 1994-2012 1997 1980
Sex M F M M F M M F
Origin Ecuador Spain Italy Turkey Belgium
Growth delay + + + - + + - +
Poikiloderma + + + + + + + - *
Onset (age) 6–7 m 1 y <1 y 18 m At birth At birth 2 y -
First localization Sun-exposedareas Cheeks Cheeks Cheeks Face Cheeks Sun-exposed areas -
Hyperkeratosis Palmo-plantar Plantar - - Plantar Palmo-plantar Palms and joints Plantar
Photosensitivity Only in infancy + + - + + - -
Hair Normal Thin Thin Normal Sparse Sparse Normal Sparse
Eyelashes Normal Sparse Sparse Normal Absent Absent Normal Sparse
Eyebrows Sparse Normal Absent Normal Sparse Sparse Normal Sparse
Onychodystrophy + - - - + + Only in infancy -
Dental defects - - - - + + Irregular end Enamel defect
Skeletal
anomalies Low bone density n.a. Low bone density -
Osteosclerosis;
Cystic-like lesion - n.a. Osteopenia
Gastrointestinal - Constipation GER - - Diarrhea; Foodintolerance in infancy
Diarrhea; Food
intolerance in infancy - Diarrhea in infancy
Cancer (onset age) - Olecranon OS (23 y) Ankle OS (19 y) - - Ulnar OS (14 y);Femur OS (17 y) -
Alveolar rhabdomyosarcoma
(12 y)
Others CD4/CD8 = 2.5keratoconus -
Tibiotalar joint
degenerative
changes
- - -
Recurrent middle ear
infections; IgA deficiency;
Knee arthritis
Hypogonadism; Chronic
anemia; Hyper-ferritinemia;
Hyper-cholesterolemia; Insulin
resistance
RECQL4 genotype c.[3236G>T];[3236G>T] c.[1048_1049del]; [1878+32_1878+55del] c.[1568G>C;1573delT]; [3021_3022del] c.[3054A>G]; [3054A>G] c.[2412_2420del]; [?]
* White nodular lesions on the skin and swelling; GER= Gastroesophageal reflux disease; OS: osteosarcoma; +: sign present; -: sign absent; n.a.: data not available.
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2.1.2. Family B
The Spanish family includes three affected siblings, a female (III-1) deceased at age 24 years and
two males, 21 (III-2) and 6 (III-3) years old (Figure 1b).
According to the clinical records, the elder sister III-1 manifested poikiloderma, photosensitivity
and delayed growth since the first year of life. The parents also reported constipation and
gastro-esophageal reflux. At 23 years, she presented with facial malar erythema with surface
telangiectasia, sparse eyelashes, thick eyebrows, hyperkeratotic lesions on both heels and on the
skin over the Achilles tendon (Table 1). Deepened investigations for pain in her left elbow revealed a
high-grade OS (T2 N0 MO G2), stage IIB that invaded fibroadipose and musculoskeletal soft tissues.
A whole-body bone scintigraphy study ruled out metastases. Treatment with the chemotherapy
regimen Adriamycin (25 mg/m2 for 3 days), Ifosfamide (1800 mg/m2 for 5 days) followed by
5-methotrexate (12 g/m2), Cisplatin-VP16 plus Mifamurtide in two doses was administered. Soon
after chemotherapy, she had diarrhea, colic-type pain, elevated liver enzymes and developed fever,
oral mucositis grade 2 and persistent bone marrow aplasia. Sepsis caused by Pseudomonas was
diagnosed. Despite treatment with antibiotics, the patient health continued to deteriorate: she
developed pneumonia, severe bone marrow aplasia, liver failure, severe mucositis with ulcers and
extensive oral erythema that precluded food swallowing, and she presented large areas of denuded
skin. Lyell’s syndrome was diagnosed, for which she received intravenous immunoglobulin treatment
at a dose of 1 g/kg/day for 4 days. Unfortunately, her condition continued to worsen and she died
a few weeks later. Test for methylenetetrahydrofolate reductase (MTHFR) revealed that she was
homozygous for the c.1298A>C polymorphism (p.(Glu429Ala)), variant associated with toxicity and
adverse drug events after methotrexate treatment [23].
Clinical history of the elder brother (III-2) recalls diffuse erythema on both cheeks at 6 months, which
spread to the entire face and evolved into the typical poikiloderma with hypo- and hyper-pigmented
skin areas and telangiectasia (Figure 1b). The patient manifested severe photosensitivity and growth
delay. There was no history of gastrointestinal disease, no plantar hyperkeratotic lesions and sexual
development was normal. On last physical examination at age 21 y, he was found to be of short
stature, with fine hair and madarosis (Table 1). Following persistent pain at his ankle, a radiographic
study was performed evidencing an eccentric, lytic focal lesion on the lateral side of the right tibia
epiphyseal-metaphyseal region. In addition, generalized low bone density and tibio-talar joint
degenerative changes were detected. Bone biopsy and immunohistochemical studies allowed the
diagnosis of low-grade fibroblastic OS. The patient underwent radical oncological surgery, but no
adjuvant chemotherapy was administered. One year after the amputation, nuclear magnetic resonance
revealed a 29 mm × 29 mm solid tumor in the popliteal space of the right knee. Bone biopsy revealed
a completely necrosed high-grade sarcoma and the supracondylar limb was amputated. The patient
is currently waiting to commence adjuvant chemotherapy treatment. Like his sister, he was found
homozygous for the c.1298A>C polymorphism (p.(Glu429Ala)) of MTHFR gene.
The youngest sibling III-3 (#39) is a 6-year-old male and presented with reticulated erythema
limited to both cheeks (Figure 1b) since he was a year and a half old, but he did not develop
photosensitivity. There is no history of growth delay, skeletal and gastrointestinal abnormalities;
hair, eyelashes and eyebrows are normal (Table 1).
2.1.3. Family C
The index case II-2 (#42) is a 31-year-old female from South Italy born to unrelated parents
originated from two closed small villages. One abortion (II-4) and two late fetal deaths in utero (II-1
and II-5) are recorded (Figure 1c).
She has poikiloderma on the cheeks (Figure 1c), sparse eyebrows and absent eyelashes, nail
dysplasia, plantar hyperkeratosis and dental defects (Table 1). Since infancy, she manifested
photosensitivity, growth delay and suffered of diarrhea. Lacrimal duct obstruction was corrected.
X-ray investigations performed at age 22 years showed several osteosclerosis nodules and cystic-like
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lesions on both femur heads, acetabula and on ischiopubic and iliopubic branches. At age 27 she had
an accidental fracture of the fifth metatarsal bone. At age 31 during her first pregnancy, she developed
gestational diabetes. Several threats of miscarriage occurred during pregnancy. The child was born at
33 weeks with an emergency cesarean section for fetal distress, and he presented with low weight and
length (both 3rd centile) and congenital hydrocephalus, which has been successfully treated.
At the last examination, she has not developed any cancer, while her younger brother (II-6,
Figure 1c) developed at age 14 an isolated OS at the right distal ulna and, 3 years later, another OS
at the femur head, causing his demise at age 18 years. According to the clinical history, the RTS
clinical phenotype of the brother was more severe than that of his sister (II-2) (Table 1). Indeed,
he presented at birth with hydrocephalus and renal tubulopathy, then he developed diarrhea, food
intolerance, iridocyclitis and chronic otitis. Besides early onset poikiloderma, absent/sparse hair,
eyelashes, eyebrows, photosensitivity, dental defects, palmo-plantar hyperkeratosis, he presented a
severe growth delay which was treated with growth hormone (GH) (Geneteopin) at age 6 years for
6 months with positive results.
2.1.4. Family D
Patient #19 (IV-2) is the second child of Turkish consanguineous (first cousins) parents (Figure 1d).
At his first examination at age 3.5 years, he displayed poikiloderma on sun-exposed areas, referred
to be present since age 2, and keratoderma over phalangeal joints, palms, elbows and knees. Skin
biopsy at age 3 revealed sub-epithelial melanin deposition, vacuolar changes at basal layers and rare
keratinocyte necrosis raising the clinical diagnosis of RTS. He suffered from recurrent middle ears
infections and immunological evaluation revealed IgA deficiency, treated with monthly IV-IG infusions
for a while. At age 9, he suffered from a knee arthritis (Table 1). At age 16, corresponding to last
examination, the patient presented poikiloderma on cheeks, ears, forearms and knees (Figure 1d),
keratoderma on palms and joints and teeth with irregular ends. Poikilodermatous skin lesions were
not spread or getting worse with age. Neither eye, hair or nail problems were present that time. He was
using high factor sunblock for protecting his affected skin parts.
2.1.5. Family E
Patient #38 is a Belgian woman that presented with small stature (adult height: 159 cm), sparse
scalp hair, eyelashes and eyebrows, enamel defect and hyperkeratosis of the soles of the feet (Figure 1e).
She has no typical poikiloderma but small white lesions of the skin and swelling of the lower
limbs. She has hypogonadism, generalized osteopenia but she does not show nail abnormalities.
She suffered of diarrhea in infancy that resolved spontaneously with age. In addition chronic anemia
(Hb 9.5 g/dL), a moderate hepatosiderosis, hyperferritinemia with negative hemochromatosis genetic
test, hypercholesterolemia and insulin resistance were reported (Table 1). At the age of 12 years,
she developed an alveolar rhabdomyosarcoma grade III of the lower limb, successfully treated with
chemotherapy and surgery.
2.2. Molecular Characterization of RTS Patients
Biallelic alterations in RECQL4 gene were found in all patients from all families with the exception
of patient #38 where only one RECQL4 heterozygous alteration was detected.
Patient #29 carries the homozygous c.3236G>T substitution affecting the last nucleotide of exon
18 (Figure 1a). The unavailability of DNA from the biological parents precluded segregation analysis
of the observed alteration. This yet unreported missense variant, which should lead to the substitution
of the 1079 Serine residue, evolutionary conserved across mammals, with Isoleucine (p.(Ser1079Ile)) is
predicted to be damaging by SIFT, Polyphen2, Provean algorithms and to have a moderate functional
impact by Mutation Assessor. In addition, ESEFinder, Human Splicing Finder, Splice View and
NetGene2 predict that the c.3236G>T causes detriment of the wild-type donor splice site, inhibiting
intron 18 correct splicing. We confirmed these predictions by sequencing the RT-PCR amplicons visible
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on the agarose gel (Figure 2a, left panel). Indeed the 715 bp fragment includes the entire IVS18 sequence,
while the faster migrating product of 301bp results from skipping of exons 18 and 19 (Figure 2a, right
panel). In both cases, the reading frame is disrupted and a downstream premature termination codon is
exposed predicting the truncated protein p.Ser1079MetfsTer17 and p.Gly1019AlafsTer95, respectively.
As regards family B, the RECQL4 molecular study showed that both brothers are compound
heterozygous for the paternally inherited c.1048_1049del in exon 5 and the maternal c.1878+32_1878+
55del in IVS11 (Figure 1b). Both pathogenic variants are inferred to be present in the deceased elder
sister III-1. Both deletions have been previously reported [8,24–27], but their effect at the transcript
level has not been explored.
Sequencing of the cDNA amplified region between exon 5 and exon 7, which includes the
c.1048_1049del deletion, revealed beyond the expected sequence, an aberrant transcript lacking two
exon 5 nucleotides (Figure 2b), which is potentially translatable in the p.Arg350GlyfsTer21 protein.
As to the c.1878+32_1878+55del deletion in the small intron 11 (81 nucleotides), amplification of
the cDNA portion (exons 9–13) allowed to retrieve two different RECQL4 amplicons: the expected
486 bp fragment and a faster migrating 312 bp product (Figure 2b). Sequencing of the latter showed a
non canonical exon 10–12 junction resulting from exon 11 skipping (Figure 2b). According to ESEFinder,
the c.1878+32_1878+55del includes the branch site of IVS11 precluding, as well the small intron size,
correct splicing. The skipped transcript maintains the reading frame and, if translated, would encode
for a protein lacking 58 aa within the helicase domain (p.Ile569_Lys626del).
The index case II-2 of family C is compound heterozygous for the novel RECQL4 exon 17
c.3021_3022del, inherited from her mother, and the highly recurrent alteration [8,26,28,29] of exon 9
c.[1568G>C;1573delT] inherited from her father (Figure 1c). The same mutations are inferred to be
carried by the deceased younger brother (II-6), while the healthy younger sister (II-3) has inherited the
maternal deletion (Figure 1c).
RT-PCR and sequencing of the RECQL4 cDNA portions, encompassing exons 7–12 and 15–20,
evidenced the presence of two aberrant transcripts carrying either exon 9 or exon 17 alterations,
beyond wild-type sequences (Figure 2c). Both aberrant transcripts present a premature stop codon
and, if translated, should give origin to truncated proteins, p.[Ser523Thr;Cys525AlafsTer33] and
p.Cys1008ProfsTer24, respectively.
The homozygous c.3054A>G sequence change has been identified in patient #19 (Figure 1d).
This silent mutation involving the penultimate nucleotide of exon 17 is not present in variant databases,
and, according to in silico predictions of NetGene2 and Splice View it should cause mis-splicing due to
decreased strength of the physiological donor splice site of intron 17. The Human splicing finder tool
also predicts interference with splicing, by exonic splicing enhancer (ESE) modification.
High resolution CGH-array and Genome-wide SNP-array did not highlight rare pathogenic CNVs
contributing to the RTS phenotype.
Finally, PCR amplifications of whole RECQL4 region of patient #38 has permitted to identify only
one heterozygous alteration in exon 14, the c.2412_2420del deletion (Figure 1e). This pathogenic
variant is not reported in literature but is included in databases as variant rs766312203 with
uncertain significance: allele frequency in ExAc is 0.00004628 (=1/21607). The aberrant transcript
should be translated in a protein (p.(Ala805_Arg807del)) missing 3 amino acids within the RECQL4
helicase domain.
High resolution CGH-array analysis did not evidence unreported genomic rearrangements/CNVs
with a possible contributing role in the observed phenotype (data not shown).
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Figure 2. RECQL4 transcript analyses in RTS families A, B, C. (a) Agarose gel showing two aberrant
RT-PCR products in patient #29 homozygous for c.3236G>T alteration: sequencing of the slower
migrating band shows intron 18 retention (76 nucleotides) while electropherogram obtained from
the faster migrating band reveals skipping of exons 18 (181 nt) and 19 (157 nt). (b) Left panel:
electopherogram of the RT-PCR product (exons 5–7) including the heterozygous c.1048_1049del
of patient #39 highlights the lack of two nucleotides (in red). The wild-type sequence refers
to the other allele of the patient carrying a downstream deletion. Right panel: agarose gel of
the RT-PCR product of exons 9–13 amplicon and electropherogram of the faster migrating band
showing a mis-spliced transcript lacking exon 11 (174 nt) due to the IVS11 c.1878+32_1878+55del
deletion. The wild-type amplicon refers to the other patient allele carrying an upstream deletion.
(c) Left panel: electropherogram of the RT-PCR product (exons 7–12) including the heterozygous
c.[1568G>C;1573delT] of patient #42 highlights the out-of-frame change (in red) transversion and
the in cis close deletion. The wild-type sequence refers to the other allele of the patient carrying the
downstream exon 17 deletion. Right panel: electropherogram of the RT-PCR product (exons 15–20)
including the heterozygous c.3021_3022del of the patient. The wild-type sequence refers to the other
patient allele with the upstream exon 9 transversion/deletion. MW: molecular weight markers; C+:
positive control (cDNA of a healthy individual); C-: negative control (no template added).
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3. Discussion
The RTS-II patients herein described well summarize the remarkable clinical breadth of
Rothmund-Thomson syndrome including mild as well as severe phenotypes at high risk for tumor
development, primarily dependent on the pathogenic variants at the causative RECQL4 gene.
Patients #19 and #29 presenting with a phenotype mainly restricted to cutaneous alterations,
are homozygous for the unreported pathogenic variants c.3054A>G, in exon 17, and c.3236G>T, in
exon 18, hence sparing the helicase domain, encoded by RECQL4 exons 8-15. Both alterations lead to
mis-splicing which is predicted by several softwares in the case of patient #19 and is demonstrated for
patient #29 (Figure 2a). In both cases mis-splicing impacts the RECQL4 C-terminal region (RQC) which
comprises a zinc-binding domain and a winged helix domain involved in protein–protein interactions
and regulation of the helicase activity, respectively [20]. Identification of pathogenic variants affecting
the RQC region, especially in homozygous state, is helpful to dissect the function of RECQL4 domains
less explored than the key helicase domain, but involved in its regulation. We can infer by our young
adult patients #19 and #29 presenting with an overall mild phenotype, that their splicing variants,
though much less deleterious compared to truncating mutations, are able to reproduce all the main
cutaneous findings of RTS, likely due to defective function of this RQC terminal region. Moreover,
we also speculate that a putative residual helicase activity of the proteins encoded by the observed
aberrant transcripts might contribute to the mild phenotype of patients #19 and #29.
Instead, a severe phenotype characterizes the affected individuals of families B and C.
Osteosarcoma developed in two siblings of family B, found to be compound heterozygous for
c.1048_1049del and c.1878+32_1878+55del deletions in exon 5 and intron 11, and in the index case
of family C, carrying the recurrent complex c.[1568G>C;1573delT] and the novel c.3021_3022del
alterations in exons 9 and 17.
Out of these pathogenic variants, two (c.[1568G>C;1573delT]; c.1878+32_1878+55del) directly
impact and one (c.1048_1049del) leads to the lack of the helicase domain confirming the known
assumption that patients with at least one RECQL4 truncating mutation disrupting the helicase domain
have an increased risk to develop osteosarcoma at young age (mean age 11 y) [2]. Moreover, these
three alterations have been already reported in literature in RTS patients with tumor outcome, as
surveyed in Table 2.
Both pathogenic variants of affected members from family B modify the helicase coding sequence
and should contribute to cancer development. The IVS11 c.1878+32_1878+55del deletion has been
reported only once in a patient who developed OS in childhood, while out of the eight cases in
the literature with c.1048_1049del deletion in exon 5 only one adult patient developed Hodgkin’s
lymphoma at 35 years: the others may not have developed tumors due their young age (<13 y) at
the analysis timepoint. It is worth noting that the c.1048_1049del allele is transcribed in an aberrant
transcript with a premature stop codon escaping, at least partially, nonsense mediated decay (NMD),
as we detected it by RT-PCR analysis, while the transcript of the c.1878+32_1878+55del allele leading
to the internal in-frame deletion of exon 11 should not trigger NMD.
Moreover, the transcript carrying r.1048_1049del deletion might potentially be translated into a
prematurely truncated protein that is predicted to lack the helicase domain and the lysine-rich region
of nuclear targeting signal 2, which should cause cytoplasmic RECQL4 accumulation upon acetylation
of the lysine residues (K376, K380, K382, K385, K386) by the p300 acetyltransferase [18].
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Table 2. Survey of tumor incidence in literature RTS patients carrying the same pathogenic variants of
our patients with osteosarcoma outcome (families B and C).
Patient
Code
Age at
Analysis Cancer Pathogenic Variant I Pathogenic Variant II Reference
FCP-195 1 y - c.1048_1049del ex 5 p.(Q757Ter) ex 14 [8]
Pt 10 13 y - c.1048_1049del ex 5 p.(Q757Ter) ex 14 [8]
Pt 13 4 y - c.1048_1049del ex 5 p.(Gln800Ter) ex 14 [8]
RTS 13 y - c.1048_1049del ex 5 p.(Gln757Ter) ex 14 [25]
RTS 6 y - c.1048_1049del ex 5 c.1391-1G>A IVS7 [24]
Pt 13 5 y - c.1048_1049del ex 5 p.(Gln800Ter) ex 14 [26]
RTS 1 34 y HL 35 y
c.1048_1049del ex 5 c.1391-1G>A IVS7 [27]
RTS 2 5 y -
#39 III-1 24 y † OS 23 y
c.1048_1049del ex 5 c.1878+32_1878+55del IVS11 This
work#39 III-2 22 y OS 19 y
#39 III-3 7 y -
FCP-210 - OS 8 y c.1718delA ex 11 c.1878+32_1878+55del IVS11 [8]
#42 II-2 31 y -
c.[1568G>C;1573delT] ex 9 c.3021_3022del ex 17 This
work#42 II-6 18 y † OS 14 y, 17 y
AS517 - OS 13 y
c.[1568G>C;1573delT] ex 9 p.(Leu926Arg) ex 16 [28]
AS518 10 y -
AS287 32 y - c.[1568G>C;1573delT] ex 9 p.(Gln757Ter) ex 14 [28]
RTS 14 y OS 10 y c.[1568G>C;1573delT] ex 9 p.(Gln757Ter) ex 14 [30]
II-1 21 y OS 21 y
c.[1568G>C;1573delT] ex 9 c.1391-1G>A IVS7 [8]
II-2 9 y † OS 7 y
FCP-129 - OS 4 y c.[1568G>C;1573delT] ex 9 p.(Gln757Ter) ex 14 [8]
FCP-153 - OS 20 y
c.[1568G>C;1573delT] ex 9 c.1391-1G>A IVS7 [8]
FCP-153
sibling - OS 9 y
Pt 1 19 y - c.[1568G>C;1573delT] ex 9 c.2059-1G>C IVS12 [8]
FCP-157 10 y - c.[1568G>C;1573delT] ex 9 p.(Gln757Ter) ex 14 [8]
FCP-167 14 y - c.[1568G>C;1573delT] ex 9 c.3270delG ex 19 [8]
FCP-175 2 y - c.[1568G>C;1573delT] ex 9 p.(Gln1175Ter) ex 21 [8]
Pt 1 9 y - c.[1568G>C;1573delT] ex 9 p.(Arg1021Trp) ex 18 [8]
Pt 9 12 y - c.[1568G>C;1573delT] ex 9 c.84+6del16 IVS1 [8]
Pt 11 11 y - c.[1568G>C;1573delT] ex 9 p.(Gln821Ter) ex 14 [8]
Pt 2 6 y - c.[1568G>C;1573delT] ex 9 p.(Cys511Arg) ex 9 [29]
Pt 3 6 y - c.[1568G>C;1573delT] ex 9 p.(Trp412Ter) ex 6 [29]
Pt 6 21 y - c.[1568G>C;1573delT] ex 9 c.2059-1G>A IVS12 [29]
Pt 9 3 y - c.[1568G>C;1573delT] ex 9 p.(Arg1021Trp) ex 18 [29]
Pt 14 8 y - c.[1568G>C;1573delT] ex 9 c.1930_1935dup ex 12 [26]
†: demise; OS: osteosarcoma; HL: Hodgkin’s lymphoma.
In family C, where only one of two affected siblings developed OS at young age, the helicase
domain is perturbed by the paternal exon 9 c.[1568G>C;1573delT] alteration, which is definitely the
most recurrent RECQL4 pathogenic variant [1]. It has been associated to RTS and so far reported in
21 patients, seven of whom developed OS. Furthermore, c.[1568G>C;1573delT] has been found in
heterozygous condition in one RAPADILINO patient [8] and 4 BGS siblings [8,31], comprising two
fetuses and one child deceased at 3 years of age. The maternal c.3021_3022del in exon 17 is unreported
and falls in gene region coding for RECQL4 C-terminus.
Table S1 provides a general overview of the RECQL4 pathogenic variants detected to our
knowledge in 35 patients who developed cancer presenting with all the three RECQL4-associated
diseases (28 RTS, 6 RAPADILINO and 1 BGS patients) [8,26–28,30,32–34]. Out of 35 RECQL4-mutated
patients, 34 carried at least one pathogenic variant affecting the helicase domain, confirming the
association between deleterious mutations in the RECQL4 gene and cancer predisposition first assessed
by Wang in 2003 [35].
Switching back to the RTS cancer families herein described, consistent with the location and
predicted effect of the pathogenic variants the cancer predisposition appears more penetrant in family
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B where two siblings developed OS versus one in family C, as a second RTS affected member is cancer
free at current age of 31 years. Nevertheless in both families OS, occurring at two different sites, was
fatal at young age to the affected sibling. Apart cancer outcome, the phenotype of affected members is
complete and severe in both families, also including rare RTS findings, although intrafamilial variability
(for instance in gastrointestinal signs in family B siblings) is apparent and can be only ascribed to
modifiers loci not shared by the siblings.
Cancer has also occurred in patient #38 who however developed rhabdomyosarcoma, an
RTS-unusual tumor, and displays atypical skin RTS phenotype. Though she manifests the additional
clinical features required to establish the RTS diagnosis as sparse/absent hair/eyelashes/eyebrows,
hyperkeratosis, growth delay, diarrhea in infancy, bone, teeth and nail defects, she does not show the
classic poikiloderma. Even if representing the hallmark cutaneous defect of RTS, poikiloderma is quite
rare in the RECQL4-related disorders RAPADILINO [36] and Baller-Gerold [9] making atypical skin
changes in suspected RTS patients worth to be considered.
Patient #38 is also unsolved by molecular diagnosis as she is heterozygous carrier of a very
rare c.2412_2420del pathogenic variant and is here included for sake of completeness, in keeping
with the literature where at least 11 patients carrying only one heterozygous mutation have been
described [26,29,35,37]. Interestingly, the c.2412_2420del alteration of patient #38 falls in the region
encoded by exon 14, which undergoes a physiological alternative splicing. An increased amount of the
alternative in-frame transcript, encoding for a likely functional protein lacking 66 amino acids of the
helicase domain, has been detected in two RTS siblings characterized by mild phenotype carrying the
c.2272C>T mutation which is abolished by exon 14 alternative splicing [38]. Unfortunately, patient #38
RNA was not available to investigate an expression change of the physiological alternative transcript
r.2266_2463del.
In conclusion, deep phenotyping of a small cohort of patients with the ultra-rare Rothmund-
Thomson type-II syndrome emphasizes the remarkably different clinical presentation with demand
in some instances of patient management by an integrated team of professionals, including the
oncologist. Characterization at DNA and RNA level of patients’ pathogenic variants is a valuable tool
to predict their effect on overall phenotype and disease evolution, allowing for providing patients
with oncological surveillance and personalized care of medical complications. Last, expanding
the repertoire of RECQL4 gene variants affecting protein domains which a scarcely known role
is instrumental to address functional studies [39] aimed at precise mapping of intertwined functions of
the multifunctional RECQL4 protein.
4. Materials and Methods
4.1. Biological Material from Affected and Healthy Individuals from RTS Families
Affected individuals of five unrelated families (A, B, C, D, E) with a clinical diagnosis of suspected
or probable RTS were referred to our laboratory by clinical geneticists and dermatologists. All patients
and their family members were enrolled in this study after obtainment of appropriate informed consent
to genetic analysis and photos collection.
4.2. DNA Isolation and RECQL4 Mutational Analysis
Genomic DNA from peripheral blood of the index cases and their family members was
isolated with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA) according to
standard protocols.
The entire RECQL4 gene (NG_016430.1) (21 exons and 20 introns with the exception of IVS12
minisatellite) was amplified using GoTaq® Flexi DNA polymerase (Promega) and primers listed in
Table S2.
PCR products were sequenced according to the manufacture’s protocol using Big Dye Terminator
v.3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and primers listed in Table S2
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on the ABI PRISM 3130 sequencer (Applied Biosystems). Electropherograms were analysed with
ChromasPro software 1.7.4 (Technelysium Pty Ltd., South Brisbane, Australia) using the wild type
sequence of the RECQL4 gene (GenBank: NG_016430.1) as reference.
Sequence variants were described according to HGVS nomenclature guidelines (http://varnomen.
hgvs.org/) [40].
Pathogenic variants were included in LOVD database (http://lovd.nl/RECQL4) [41].
4.3. Cell Cultures
EBV-transformed lymphoblastoid cell lines (LCLs) were established from peripheral blood
lymphocytes of patient #42, her parents and five healthy controls.
LCLs were cultured in complete RPMI-1640 medium (EuroClone, Milano, Italy) supplemented
with 10% fetal bovine serum (Lonza, Walkersville, MD, USA) and 1% penicillin, streptomycin and
ampicillin in a 37 ◦C humidified incubator with 5% CO2.
4.4. RNA Isolation, RT-PCR and cDNA Analysis
TRI Reagent (Sigma, St Louis, MO, USA) was used to isolate total RNA of patients #29, #39, his
affected brother and his parents, #42, healthy controls from white blood cells, and from LCLs of family
C, according to manufacturer’s protocols.
After DNase I (RNase-free, New England Bio-Labs, Inc., Ipswich, MA, USA) treatment, 500 ng
of total RNA were used to synthesize cDNA using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) with random hexamers. All samples were reverse transcribed in two
independent experiments.
Different fragments of RECQL4 transcript were amplified using GoTaq®Flexi DNA polymerase
(Promega) and primers listed in Table S3.
Amplicons were run on 2% agarose gel, the bands were eluted with MinElute Gel Extraction Kit
(Qiagen, Milano, Italy) and then sequenced as described above.
Nucleotide sequences were compared to the major RECQL4 transcript reference sequence
[GenBank: NM_004260.3].
4.5. Bioinformatic Analyses
ExAC Browser of Broad Institute (http://exac.broadinstitute.org/gene/) and 1000 Genomes
database (http://www.1000genomes.org/home) [42] were checked to assess the presence/absence of
detected alterations in variations repositories.
To predict the effect of the identified mutations at protein level, the bioinformatics tools SIFT
(http://sift.jcvi.org/) [43], Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) [44], Provean (http:
//provean.jcvi.org/index.php) [45], Mutation Assessor (http://mutationassessor.org/r3/) [46] and
Mutalyzer (https://mutalyzer.nl/) [47] were applied.
To predict the impact of mutation on splicing ESEFinder (http://rulai.cshl.edu/cgi-bin/tools/
ESE3/esefinder.cgi?process=home) [48], Human Splicing Finder (http://www.fruitfly.org/seq_tools/
splice.html) [49], Splice View (http://www.umd.be/HSF/), and NetGene2 (http://www.cbs.dtu.dk/
services/NetGene2/) [50] were consulted.
4.6. High-Resolution CGH-Array
As regards patients #19 and #38, high-resolution array-based comparative genomic hybridization
(CGH-array) analysis was performed, on 700 ng genomic blood DNA, using the high resolution
SurePrint G3 Human CGH Microarray Kit 2× 400 K in accordance with the manufacturer’s instructions.
(Agilent Technologies, Palo Alto, CA, USA). Images were captured using the Agilent Feature Extraction
3.0.5.1 software and chromosomal profile was acquired using the ADM-2 algorithm provided by
Agilent CytoGenomics v.3.0.6.6 software (Agilent Technologies).
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Coordinates of Copy Number Variants (CNVs) referred to the Human Genome assembly
GRCh37/hg19 (https://genome.ucsc.edu/). CNV classification was performed according to the
Database of Genomic Variants (http://projects.tcag.ca/variation/, release March 2016) to exclude
common polymorphic CNVs with a frequency >1% in healthy control subjects. The CNV classification
by clinical relevance was performed according to the guidelines suggested by Miller [51] and
successively by the American College of Medical Genetics [52].
4.7. SNP-Array
SNP-array analysis was performed on samples of family #19 using the Human OmniExpress
Exome-8 Bead Chip (Illumina Inc., San Diego, CA, USA) containing 960,919 loci derived from phases
I, II and III of the International HapMap project. The array includes over 274,000 functional exonic
markers, delivering unparalleled coverage of putative functional exonic variant selected from 12,000
individual exome and whole-genome sequences.
A total of 200 ng of gDNA (50 ng/µL) for each sample was processed according to Illumina’s
Infinium HD Assay Super protocol. Normalization of raw image intensity data, genotype clustering
and individual sample genotype calls were performed using Illumina’s Genome Studio software
v2011.1 (cnvpartition 3.2.0). The CNVs were mapped to the human reference genome hg19 and
annotated with UCSC RefGene. Allele detection and genotype calling were performed with
Genome Studio software, B allele frequencies (BAFs) and log R ratios were exported as text files
for PennCNV analysis.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/19/4/1103/
s1.
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